Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5532]

Durvalumab improves survival and delays progression in limited-stage small cell...

Dr Eva-Lotte Buchmeier - Hospitals of the City of Cologne gGmbH, Cologne...

Durvalumab improves survival and delays progression in limited-stage small cell lung cancer ( Dr Eva-Lotte Buchmeier - Hospitals of the City of Cologne gGmbH, Cologne, Germany )

Osimertinib plus local therapy improves outcomes in EGFR-mutant metastatic lung...

Dr Saumil Gandhi - University of Texas MD Anderson Cancer Center, Houston, USA

Osimertinib plus local therapy improves outcomes in EGFR-mutant metastatic lung cancer ( Dr Saumil Gandhi - University of Texas MD Anderson Cancer Center, Houston, USA )

Pembrolizumab plus chemotherapy delivers lasting benefit in early-stage NSCLC

Dr Margarita Majem - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Pembrolizumab plus chemotherapy delivers lasting benefit in early-stage NSCLC ( Dr Margarita Majem - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain )

Becotarug plus osimertinib shows survival benefit in EGFR exon 20 insertion...

Dr Jinhui Xue - Sun Yat-sen University Cancer Center, Guangzhou, China

Becotarug plus osimertinib shows survival benefit in EGFR exon 20 insertion lung cancer ( Dr Jinhui Xue - Sun Yat-sen University Cancer Center, Guangzhou, China )

TQB2922 combination shows high response rates in EGFR-mutant lung cancer after...

Dr Jinhui Xue - Sun Yat-sen University Cancer Center, Guangzhou, China

TQB2922 combination shows high response rates in EGFR-mutant lung cancer after tyrosine kinase inhibitor resistance ( Dr Jinhui Xue - Sun Yat-sen University Cancer Center, Guangzhou, China )

SHR-A2009 plus EGFR tyrosine kinase inhibitor shows promising activity in EGFR...

Prof Yi-Long Wu - Guangdong Lung Cancer Institute, Guangzhou, China

SHR-A2009 plus EGFR tyrosine kinase inhibitor shows promising activity in EGFR-mutant lung cancer ( Prof Yi-Long Wu - Guangdong Lung Cancer Institute, Guangzhou, China )

Sevabertinib shows manageable diarrhoea without impacting efficacy in HER2...

Prof Nicolas Girard - Institut Curie, Paris, France

Sevabertinib shows manageable diarrhoea without impacting efficacy in HER2-mutant lung cancer ( Prof Nicolas Girard - Institut Curie, Paris, France )

Subcutaneous amivantamab plus lazertinib shows durable responses in EGFR-mutant...

Prof Nicolas Girard - Institut Curie, Paris, France

Subcutaneous amivantamab plus lazertinib shows durable responses in EGFR-mutant advanced lung cancer ( Prof Nicolas Girard - Institut Curie, Paris, France )

Distinct lung microbiome patterns identified in Portuguese patients with lung...

Dr Telma Sequeira - CUF Tejo, Lisbon, Portugal

Distinct lung microbiome patterns identified in Portuguese patients with lung cancer ( Dr Telma Sequeira - CUF Tejo, Lisbon, Portugal )

T-cell engagers in lung cancer: Strategies to prevent and manage toxicities

Dr Myung-Ju Ahn - Sungkyunkwan University School of Medicine, Seoul, South Korea

T-cell engagers in lung cancer: Strategies to prevent and manage toxicities ( Dr Myung-Ju Ahn - Sungkyunkwan University School of Medicine, Seoul, South Korea )

Cracking the code: Bispecific immunotherapy in small cell lung cancer

Prof Helena Linardou - Metropolitan Hospital, Athens, Greece

Cracking the code: Bispecific immunotherapy in small cell lung cancer ( Prof Helena Linardou - Metropolitan Hospital, Athens, Greece )

ATR inhibitor plus durvalumab does not improve survival over docetaxel in...

Prof Benjamin Besse - Institut Gustave Roussy, Villejuif, France

ATR inhibitor plus durvalumab does not improve survival over docetaxel in advanced NSCLC ( Prof Benjamin Besse - Institut Gustave Roussy, Villejuif, France )

More from ecancer